Trends in management of patients with new‐onset refractory status epilepticus (NORSE) from 2016 to 2023: An interim analysis
Hanin A, Jimenez A, Gopaul M, Asbell H, Aydemir S, Basha M, Batra A, Damien C, Day G, Eka O, Eschbach K, Fatima S, Fields M, Foreman B, Gerard E, Gofton T, Haider H, Hantus S, Hocker S, Jongeling A, Aparicio M, Kandula P, Kang P, Kazazian K, Kellogg M, Kim M, Lee J, Marcuse L, McGraw C, Mohamed W, Orozco J, Pimentel C, Punia V, Ramirez A, Steriade C, Struck A, Taraschenko O, Treister A, Wainwright M, Yoo J, Zafar S, Zhou D, Zutshi D, Gaspard N, Hirsch L. Trends in management of patients with new‐onset refractory status epilepticus (NORSE) from 2016 to 2023: An interim analysis. Epilepsia 2024, 65: e148-e155. PMID: 38837761, DOI: 10.1111/epi.18014.Peer-Reviewed Original ResearchNew-onset refractory status epilepticusSecond-line immunotherapyKetogenic dietStatus epilepticusDuration of status epilepticusRefractory status epilepticusStatus epilepticus onsetManagement of patientsEvolving treatment landscapeTreatment landscapeImmunotherapyConsensus recommendationsInterim analysisPatientsPatient outcomesAnakinraEpilepticusShort durationMedianORCIDietDaysTocilizumabIncreased use
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply